Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 9.1% | 3.3% | 8.3% |
| 2025 | 2024 |
|---|---|
| 8.3% | 14.7% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 9.1% | 3.3% | 8.3% |
| 2025 | 2024 |
|---|---|
| 8.3% | 14.7% |
The Artisan Small Cap Fund posted strong absolute returns in Q4 2025, outperforming both the Russell 2000 Growth Index and Russell 2000 Index. Performance was broad-based across the portfolio, with information technology leading outperformance driven by semiconductor company MACOM. For the full year, the portfolio generated strong absolute returns but trailed benchmarks primarily due to security selection within healthcare, overweight in IT, and software performance. The team maintains high conviction in their profit cycle approach, noting that Q4 market leadership shifted back toward companies exhibiting durable profit cycles rather than lower quality, risk-on environments. Key themes include AI-related opportunities in semiconductors and data centers, defense and aerospace positioning for multiyear growth, and biotechnology investments early in compelling product launch cycles. The team remains focused on hunting profit cycles within franchise companies at reasonable valuations, believing this approach should enable outperformance over a full market cycle.
The fund seeks to invest in companies that possess franchise characteristics, are benefiting from an accelerating profit cycle and are trading at a discount to private market value, focusing on security selection and capital allocation while overlaying broad knowledge of the global economy.
Entering 2026, we remain focused on our time-tested process of hunting profit cycles within franchise companies at understandable valuation assumptions. Over any measurable period of time, we believe this approach should enable the portfolio to outperform over a full market cycle. We are back or nearly back to where interesting profit cycles will lead once again, rather than lower quality stocks.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 21 2026 | 2025 Q4 | BRKR, CLBT, COCO, FLEX, GH, GWRE, HXL, INSM, IRTC, ITGR, LASR, LSCC, MOD, MTSI, PCOR, PEN, PSN, SN, STVN, VSEC | AI, Biotechnology, defense, growth, healthcare, profit cycles, small cap, technology |
MTSI INSM COCO STVN PSN GWRE |
AI-related capital spending remains an area of active debate entering 2026. Investors continue to weigh strong industry momentum against concerns about circular financing dynamics and… |
| Oct 21 2025 | 2025 Q3 | 4350 JP, ALAB, ASND, CGNX, CWAN, IBP, INSM, LOAR, LSCC, MDGL, MOD, MTSI, SN, WAY, WING | AI, Biotech, Health Care, industrials, small caps |
LSCC MOD INSM TWST MTSI CGNX OLLI LSCC MOD INSM TWST MTSI CGNX OLLI |
The fund posted strong absolute but weaker relative returns as speculative small-cap stocks led markets. Managers emphasized profit-cycle investing, focusing on companies with durable growth… |
| Jul 22 2025 | 2025 Q2 | BIRK, BWXT, CWAN, FLEX, FRSH, HALO, IOVA, IRTC, LSCC, MDGL, MTSI, SAIA, STVN, TTAN, WING | cash flow, fundamentals, Quality, small caps, Valuation discipline |
FLEX MTSI IRTC CWAN BWXT WING MDGL BIRK SVTA STVN GWRE |
The letter highlights a challenging environment where speculative stocks outperformed quality businesses. Management remains committed to owning high-quality small-cap companies with strong cash flows and… |
| Mar 31 2025 | 2025 Q1 | ARIS, ASND, BROS, DAY, FRSH, FTAI, GWRE, HALO, KTOS, MTSI, SG, VCYT | - | - | - |
| Dec 31 2024 | 2024 Q4 | ALAB, ARGX, COCO, CROX, FLS, GTLB, HALO, IPAR, ITGR, LSCC, NOVT, PSN, SN, TYL, VCYT, VSEC | - | - | - |
| Sep 30 2024 | 2024 Q3 | CIGI, ELF, GWRE, HLNE, IBP, LSCC, RYTM, SN, VCYT | - | - | - |
| Jul 20 2024 | 2024 Q2 | BSY, COCO, ETSY, GWRE, IOVA, LSCC, NTBL, SMCI, TWST, WING | - | - | - |
| Apr 15 2024 | 2024 Q1 | ARGX, BL, CCCS, ELF, FRPT, HALO, IPGP, LSCC, MPWR, MYRG, PCOR, RGEN, SHLS, SMAR, VMI | - | - | - |
| Dec 31 2023 | 2023 Q4 | ARGX, BL, ELF, FRPT, HALO, IPGP, LSCC, MYRG, NQG GR, NTBL, PCOR, SHLS, SMAR, VMI, WING | - | - | - |
| Sep 30 2023 | 2023 Q3 | 02B GR, 096 GR, ARGX, CCCS, EXAS, GNRC, GWRE, LSCC, MTSI, NTBL, NVST, PCOR, SPXC, STVN, SWAV, WCC, WMC | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIThe extended federal government shutdown added volatility during what was otherwise a risk-on environment, with a mid-quarter shift in market behavior for AI-related equities as the exuberant narrative evolved to one more balanced in assessing the technology's enormous potential against staggering capital spending plans and high expectations. The team initiated a position in Credo Technology as a more diversified way to gain exposure to strong trends in AI-connectivity. |
Connectivity Semiconductors Infrastructure Capital Spending |
BiotechnologyBiotech delivered its best quarter in five years, benefiting from improving interest rates, easing regulation enabling more M&A activity, and excitement around AI's promise in drug discovery. The portfolio nearly doubled its biotech exposure during the quarter as more opportunities presented themselves in this improving environment. |
Drug Discovery M&A Interest Rates Regulation Pharmaceuticals | |
DefenseThe team initiated a position in Curtiss-Wright, believing the company is entering a period where multiple near-term growth drivers are converging, including rising defense budgets, commercial aerospace production ramps, nuclear power plant life extensions and new builds, and submarine production. |
Defense Budgets Aerospace Nuclear Submarines | |
SemiconductorsMACOM Technology Solutions rose nearly +40% as the company experienced broad-based demand, similar to many semiconductor companies in 2025. The team exited Astera Labs following industry conference presentations that suggested emerging competitive risks and concerns over single customer concentration, while initiating a position in Credo Technology for AI-connectivity exposure. |
Demand Competition Connectivity Customer Concentration | |
| 2025 Q3 |
AIThe extended federal government shutdown added volatility during what was otherwise a risk-on environment, with a mid-quarter shift in market behavior for AI-related equities as the exuberant narrative evolved to one more balanced in assessing the technology's enormous potential against staggering capital spending plans and high expectations. The team initiated a position in Credo Technology as a more diversified way to gain exposure to strong trends in AI-connectivity. |
Connectivity Semiconductors Infrastructure Capital Spending |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech | |
Small CapsThe fund invests in a portfolio of competitively advantaged small and medium-sized businesses, which remained out of favor for most of the quarter. The strategy of owning leading small-cap businesses has been the foundation since inception, delivering 354 basis points of annual outperformance over the benchmark since inception despite recent headwinds. |
Growth Outperformance Benchmark Russell Businesses | |
| 2025 Q2 |
QualityThe portfolio has shifted toward higher quality businesses with better profitability, lower leverage, and less volatile earnings. Quality stocks underperformed significantly in 2025, creating attractive entry points for value investors. The manager maintains price discipline while seeking quality companies trading at discounts to intrinsic value. |
Quality Profitability Leverage Earnings |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | OLLI | Ollie’s Bargain Outlet Holdings Inc. | Consumer Discretionary | Broadline Retail | Bull | NASDAQ | disruption, Loyalty, Off-price retail, Sourcing, Store growth, Trade-down | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | SVTA | ServiceTitan, Inc. | Other | Application Software | Bull | NYSE | ARR, expansion, Payments, Software, Vertical_saas | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | LSCC | Lattice Semiconductor Corp. | Information Technology | Semiconductors | Bull | NASDAQ | AI data centers, Destocking, FPGAs, Inflection, Margins, robotics | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | STVN | Stevanato Group S.p.A. | Health Care | Life Sciences Tools & Services | Bull | NYSE | biologics, Equipment, growth, Margins, Packaging | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | MOD | Modine Manufacturing Co. | Consumer Discretionary | Electrical Components & Equipment | Bull | NYSE | Capacity, Cooling, data centers, hyperscale, Revenue upgrade, secular growth | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | GWRE | Guidewire Software, Inc. | Information Technology | Application Software | Bull | NYSE | Cloud_transition, Fintech, Insurance, Margins, SaaS | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | INSM | Insmed Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, Bronchiectasis, Commercialization, operating leverage, pipeline, TAM | Login |
| Jan 21, 2026 | Fund Letters | Craigh Cepukenas | MTSI | MACOM Technology Solutions Holdings, Inc. | Information Technology | Semiconductors | Neutral | NASDAQ | Cycles, Execution, Margins, semiconductors, valuation | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | TWST | Twist Bioscience Corp. | Health Care | Life Sciences Tools & Services | Bull | NASDAQ | life sciences, Margins, Ngs, Partnerships, scale, Synthetic dna | Login |
| Jan 21, 2026 | Fund Letters | Craigh Cepukenas | INSM | Insmed Incorporated | Health Care | Biotechnology | Bull | NASDAQ | Adoption, biotechnology, Drug launch, pipeline, Pulmonary | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | MTSI | MACOM Technology Solutions Holdings Inc. | Information Technology | Semiconductors | Bull | NASDAQ | Analog rf, design wins, Fab transition, Margins, Optical, recovery | Login |
| Jan 21, 2026 | Fund Letters | Craigh Cepukenas | COCO | The Vita Coco Company, Inc. | Consumer Staples | Beverages | Bull | NASDAQ | Beverages, Branding, Distribution, tariffs, Volume | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | CGNX | Cognex Corp. | Information Technology | Electronic Equipment, Instruments & Components | Bull | NASDAQ | AI enablement, Automation, Cost Reduction, Cycle recovery, Machine vision, Sme adoption | Login |
| Jan 21, 2026 | Fund Letters | Craigh Cepukenas | STVN | Stevanato Group S.p.A. | Health Care | Health Care Supplies | Bull | New York Stock Exchange | biologics, Glp1, healthcare, Packaging, Reimbursement | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | OLLI | Ollie’s Bargain Outlet Holdings Inc. | Consumer Discretionary | Broadline Retail | Bull | NASDAQ | disruption, Loyalty, Off-price retail, Sourcing, Store growth, Trade-down | Login |
| Jan 21, 2026 | Fund Letters | Craigh Cepukenas | PSN | Parsons Corporation | Industrials | Engineering & Construction | Bull | New York Stock Exchange | backlog, Contracts, cybersecurity, Defense, infrastructure | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | FLEX | Flex Ltd. | Information Technology | Electronic Manufacturing Services | Bull | NASDAQ | Demand, diversification, manufacturing, Margin_expansion, Reshoring | Login |
| Jan 21, 2026 | Fund Letters | Craigh Cepukenas | GWRE | Guidewire Software, Inc. | Information Technology | Application Software | Bull | New York Stock Exchange | Discipline, Insurance, Modernization, Software, valuation | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | MTSI | MACOM Technology Solutions Holdings Inc. | Information Technology | Semiconductors | Bull | NASDAQ | Compound_semiconductors, datacenter, Defense, Margins, Telecom | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | LSCC | Lattice Semiconductor Corp. | Information Technology | Semiconductors | Bull | NASDAQ | AI data centers, Destocking, FPGAs, Inflection, Margins, robotics | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | IRTC | iRhythm Technologies, Inc. | Health Care | Health Care Equipment | Bull | NASDAQ | Cardiology, diagnostics, Digital_health, growth, Reimbursement | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | MOD | Modine Manufacturing Co. | Consumer Discretionary | Electrical Components & Equipment | Bull | NYSE | Capacity, Cooling, data centers, hyperscale, Revenue upgrade, secular growth | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | CWAN | Clearwater Analytics Holdings Inc. | Information Technology | Financial Software | Bull | NASDAQ | Accounting, Data, Fintech, Integration, SaaS | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | INSM | Insmed Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, Bronchiectasis, Commercialization, operating leverage, pipeline, TAM | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | BWXT | BWX Technologies, Inc. | Industrials | Aerospace & Defense | Bull | NYSE | backlog, Defense, Monopoly, Nuclear, Policy | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | TWST | Twist Bioscience Corp. | Health Care | Life Sciences Tools & Services | Bull | NASDAQ | life sciences, Margins, Ngs, Partnerships, scale, Synthetic dna | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | WING | Wingstop Inc. | Consumer Discretionary | Restaurants | Bull | NASDAQ | Branding, Digital, Franchising, Restaurants, Unit_growth | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | MTSI | MACOM Technology Solutions Holdings Inc. | Information Technology | Semiconductors | Bull | NASDAQ | Analog rf, design wins, Fab transition, Margins, Optical, recovery | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | MDGL | Madrigal Pharmaceuticals, Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, Efficacy, Fibrosis, Launch, MASH | Login |
| Oct 21, 2025 | Fund Letters | Craigh Cepukenas | CGNX | Cognex Corp. | Information Technology | Electronic Equipment, Instruments & Components | Bull | NASDAQ | AI enablement, Automation, Cost Reduction, Cycle recovery, Machine vision, Sme adoption | Login |
| Jul 22, 2025 | Fund Letters | Craigh Cepukenas | BIRK | Birkenstock Holding plc | Consumer Discretionary | Footwear | Bull | NYSE | Brand, DTC, expansion, Footwear, Pricing | Login |
| TICKER | COMMENTARY |
|---|---|
| BRKR | Bruker is a leading provider of advanced scientific instruments for analyzing biological and chemical samples across life sciences, diagnostics and materials research. We increased our position during the quarter, making it a small Crop holding. We believe the company's profit cycle should benefit from ongoing product innovation and recent strategic acquisitions that strengthen its long-term outlook, though they are near-term dilutive. While Bruker faced headwinds this year from softer research funding and weaker spending in the Chinese market, these pressures are expected to ease in 2026 and could ultimately become tailwinds. |
| CLBT | On core long Cellebrite's digital forensics turf, there are several major barriers to entry, and the software itself could be considered the least of them. Cellebrite is a hardware-enabled software solution that has become both a verb (to "Cellebrite" a device) and a noun (create a Cellebrite report) for its users across the globe. A defensible moat for CLBT has been its exploit library. CLBT's device unlock and extraction capability requires: Zero-day and N-day exploits for iOS and Android (often acquired from the vulnerability market or developed in-house), Hardware interposers and chip-off capabilities for physically damaged devices, Bootloader exploits that survive OS updates, Maintaining extraction support across tens of thousands of device models and firmware versions. This is expensive and requires ongoing R&D. Furthermore, with increased scrutiny on software company cash flows excluding stock based comp, CLBT "stands up" on an Enterprise Value/Free Cash Flow ex-SBC multiple (13.1x '27E), such that it is now at a >60% discount to the broader market and significantly cheaper than almost any small cap industrial stock we evaluate despite having a massive net cash position (as opposed to leverage), ~20% growth (as opposed to limited/cyclical growth) and 34% FCF margins. |
| COCO | Coconut beverage producer Vita Coco returned nearly +25% for the quarter on better-than-expected earnings and reduced concerns around potential tariff risks. |
| FLEX | Flex is a global manufacturing and supply chain solutions provider with exposure to high-margin AI and cloud data center infrastructure, particularly power and cooling systems. We began harvesting our position this quarter as its market capitalization has grown beyond our small-cap mandate. We continue to view management favorably for its focus on optimizing product mix toward higher margin, fast-growing segments such as data centers and power. |
| GH | Guardant Health, a provider of blood-based diagnostic tests for cancer, performed particularly well, driven by strong Q3 results. Its core oncology business grew revenues 30% vs. 20% in the previous quarter, an acceleration driven by innovative product enhancements. Furthermore, its colon cancer screening tests continued to perform well, growing 50% sequentially from Q2. While shares were up significantly in 2025, we remain bullish on the business, as Guardant continues to lead the charge in converting oncology testing from tissue to blood. |
| GWRE | Shares of P&C insurance software vendor Guidewire Software, Inc. declined during the quarter following strong gains earlier in the year, as the broader software sector came under pressure. After a multi-year transition period, we think Guidewire's cloud migration is largely complete. We believe cloud will be the sole path forward, with annual recurring revenue benefiting from new customer wins and migrations of existing customers to InsuranceSuite Cloud. |
| HXL | Leading contributors included holdings in the industrials sector, led by machinery companies Kennametal and Graham Corporation, as well as aerospace and defense businesses Moog and Hexcel |
| INSM | Insmed Inc., a biopharmaceutical company focused on developing and commercializing therapies for patients with rare diseases, advanced 21% over the quarter. We have been pleased with the launch of Brensocatib, a first-in-class oral medication that treats non-cystic fibrosis bronchiectasis. The reception has been positive from physicians, patients, and payers. |
| IRTC | iRhythm provides the Zio wearable cardiac monitoring devices to assist physicians in diagnosing cardiac arrhythmias that signal elevated stroke risk. The company delivered a strong quarter that included solid growth in its core services and improved cash flow trends. After a strong 2025 driven by company-specific profit-cycle tailwinds and market share gains, we trimmed the position to take profits and right-size the investment. Growth may moderate in 2026, ahead of what we expect to be another compelling product cycle beginning in 2027. |
| ITGR | Integer Holdings Corporation (ITGR), which specializes in the design, development, and production of medical technologies and components. In late October, Integer's stock sank more than 30% after the company significantly lowered its outlook for growth and margin expansion in 2026, as several products experienced slower market adoption than was expected. But management expects these headwinds to be short-lived, with a robust portfolio of higher growth and margin products coming to market, which should allow the company to get back on track. The company still expects to outgrow its industry peers by 2% while growing earnings before interest and taxes (EBIT) at twice the rate of sales. Even better, the company announced a $200 million stock repurchase authorization after the selloff, increasing our conviction that the shares are materially undervalued. This confidence drove us to increase our exposure to Integer in the quarter. |
| LASR | nLIGHT is a US-based developer of high-power semiconductor and fiber lasers. The company previously exited its unprofitable industrial laser business in China to focus on its defense segment, which we believe positions it well for profitable growth. We initiated a Garden position based on its strong franchise in non-kinetic laser weapons, an increasingly critical technology for countering drones and certain advanced missile threats, including future applications in hypersonic defense. |
| LSCC | Lattice is a fabless provider of low power field programmable gate arrays. Recent results and guidance were in line with expectations, and long-term growth drivers remain intact, including expanding data center use cases, increasing AI edge computing adoption and a gradual recovery in industrial markets. We trimmed our Crop position to maintain valuation discipline but remain invested, given attractive profit-cycle drivers and a capable new management team. |
| MTSI | Semiconductor holding MACOM Technology Solutions rose nearly +40%, as the company experienced broad-based demand, similar to many semiconductor companies in 2025. |
| PEN | Other strong performers in the quarter, primarily driven by strong earnings results, included Penumbra |
| PSN | Parsons is a technology-driven engineering firm serving the defense, intelligence and infrastructure markets, with strengths in cybersecurity, missile defense and infrastructure protection. Shares fell in Q4 after losing out on winning a $12.5 billion Federal Aviation Administration (FAA) air traffic control modernization contract, interrupting a recovery from earlier cost-cutting pressures tied to the Department of Government Efficiency initiatives. Despite not being selected as the prime integrator, we remain invested, as Parsons' long-standing relationship with the FAA positions it to capture meaningful portions of the program. |
| SN | SharkNinja is a leading consumer products company with brands spanning cleaning, beauty and kitchen appliances. We ended our multiyear campaign in SharkNinja during the quarter. The company continues to deliver one of the most innovation-driven profit cycles in the consumer spending sector, but we exited the position in line with our valuation discipline. |
| STVN | Pulling back by -22% was Stevanato Group, which manufactures glass packaging for syringes, autoinjectors, and other pharmaceutical needs. Recent revenues and earnings each exceeded expectations, though management was conservative and merely reaffirmed its guidance for the balance of its fiscal year. There may have been some advanced purchasing from customers, though Stevanato's core business grew well, and we added to our position on the weakness. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||